U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO NFORMATION DISCLOSURE STATEMENT BY APPLICANT			Complete if Known		
			Application Number	10/691,905	
			Filing Date	July 15, 2003	
ر کی ا	Submitted: October 2	24 2002	First Named Inventor	Karim Boumediene	
	Submitted. October 2	21, 2003	Group Art Unit	TBD	
se as many sheets as necessary)			Examiner Name	TBD	
STEEL TO	1 of	1	Attorney Docket Number	065691-0327	•

U.S. PATENT DOCUMENTS						
Examiner Cite No.1		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines,
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
MG	A1	U.S. 6,146,616		Msika	11-14-2000	
	A2	U.S. 5,998,396		Nakano	12-07-1999	
	A3	U.S. 5,627,289		Jeromin	05-06-1997	
	A4	U.S. 5,498,411		Rancurel	03-12-1996	· · · · · · · · · · · · · · · · · · ·
MG	A5	U.S. 5,262,163		Rancurel	11-16-1993	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
MG	A6	FR 2 231 394		12-27-1974			
	A7	EP 0 643 960		03-22-1995			
	A8	FR 2 762 512		10-30-1998		 	
1/	A9	FR 2 678 632		01-08-1993			
─ ₩	A10	GB 1 427 253		03-10-1976		1	
MG	A11	CA 2132369		03-22-1995			
						1	

		NON PATENT LITERATURE DOCUMENTS			
		item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s			
		International Search Report for PCT/FR99/03272 (WO 00/38701)			
	A13	Helen Kim et al., "Mechanisms of Action of the Soy Isoflavone Genistein: Emerging Role for its Effects Via Transforming Growth Factor-β Signaling Pathways 1-3", The American Journal of Clinical Nutrition, vol. 68, No. 6, (suppl), pgs. 1418S-1425S, (1998) © 1998 American Society for Clinical Nutrition.			
V	A14	Par H. Thiers et al., "Un Groupe D'Agents Therapeutiques Noveaux: Les Insaponifiables Des Huiles Vegetables, Leurs Carotenoids, Leurs Indetermines Administres En Solution Alcoolique", Therapie, vol 16, pgs. 235-251, 1961			
MG	A15	Pharmascience Laboratories "PIASCLEDINE 300 mg gelules," 1992, previously available at http://www2.biam2.org/www/spe11021.html			
*	A16	VIDAL, "PIAGGLEDINE 900 mg gol", available at http://www.vidal.fr/medicament/plascledine+13187.htm			

Examiner Signature	/Michel Graffeo/	,	Date Considered	12/29/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.